< Prev		CONTENTS		Source		Next >

Proteasome inhibitor

Bortezonib

Nuclear factor-kappa B pathway and response in a phase II trial of borte- zomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (Chung et al. 2010). Twenty-one of 25 enrolled patients were assessable for response; one partial response (PR, 5%), 10 stable disease (SD, 48%) and 10 progressive disease (PD, 48%). Patients with PR/SD had significantly longer survival compared with patients with PD and the regimen was well tolerated. Only one of 20 tumors was positive for HPV. Patients with PD had higher expression of NF-kappaB and epidermal growth factor receptor-associated genes in their tumors by gene expression analysis.

Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group (Gilbert et al. 2013). The response rate of bortezomib and irinotecan was 13%. One patient had a partial response to borte- zomib alone (response rate 3%). No responses were seen in patients with addition of irinotecan at time of progression on bortezomib.

Source

< Prev		CONTENTS		Source		Next >

Proteasome Inhibitors
As cells continuously produce proteins throughout their lifetime, they have also evolved mechanisms to destroy them and recycle the constituent amino acids. It is particularly important that cells can destroy signaling proteins, as otherwise many signaling pathways would be in a permanently “on”...
(Chemistry and Pharmacology of Anticancer Drugs)
Catalysts and Inhibitors of Cooperation
In order for a cooperative relationship to be established at all, it is necessary to create the right conditions to help overcome initial mistrust or to make potential partners aware of the benefits of joint activities. A good example of such activities creating a strong basis for the later effective...
(The Cluster Organization: Analyzing the Development of Cooperative Relationships)
What are the 5-alpha reductase inhibitors?
The 5-alpha reductase inhibitors are a class of medications that inhibit the enzyme 5-alpha reductase. The enzymes 5-alpha reductase are present in two isoforms: type 1 and type 2. Type 1 is found predominantly in extraprostatic tissues such as the skin and liver, although it is also found in the prostate....
(100 Questions & Answers About Mens Health: Keeping You Happy & Healthy Below the Belt)
What are the side effects of 5-alpha reductase inhibitors?
Side effects found in the first year of 5-alpha reductase inhibitor use include: decreased sexual drive (libido), increased ejaculatory dysfunction (such as smaller amount of semen ejaculated), difficulty getting an erection, breast tenderness or enlargement. One large study demonstrated that after a...
(100 Questions & Answers About Mens Health: Keeping You Happy & Healthy Below the Belt)
What are the results of BPH treatment using 5-alpha reductase inhibitor drugs?
As mentioned previously, finasteride (Proscar) and dutasteride (Avodart) are the two 5-alpha reductase inhibitors that are currently available in the United States. Both of these drugs require 3 to 6 months to see clinical beneficial effects. The Finasteride Study Group showed improvement in peak flow...
(100 Questions & Answers About Mens Health: Keeping You Happy & Healthy Below the Belt)
What effects do 5-alpha reductase inhibitor drugs have on PSA levels?
5-alpha reductase inhibitor drugs block the conversion of testosterone to DHT, which results in shrinkage of the prostate or a decrease in prostate volume. Because prostate cells make PSA, it is reasonable to assume that as the prostate gets smaller, the PSA level will decline. This is in fact what happens;...
(100 Questions & Answers About Mens Health: Keeping You Happy & Healthy Below the Belt)
Do the 5-alpha reductase inhibitors have an effect on the risk of developing prostate cancer?
A recent study called the "Prostate Cancer Prevention Trial" (PCPT) demonstrated that finasteride (Proscar) at a dose of 5mg/day decreases the likelihood of developing In patients who have been on 5-alpha reductase inhibitors for longer than 3—6 months, the PSA should remain stable and...
(100 Questions & Answers About Mens Health: Keeping You Happy & Healthy Below the Belt)
What are oral therapies for ED— specifically, the phosphodiesterase type 5 (PDE-5) inhibitors?
Currently, three oral therapies are available for the treatment of ED. The first therapy to become available was sildenafil (Pfizer's Viagra), which was approved by the FDA in 1998. Vardenafil (Bayer's Levitra) and tadalafil (Lily Icos's Cialis) were approved for use years later. All three of these oral...
(100 Questions & Answers About Mens Health: Keeping You Happy & Healthy Below the Belt)
Who is a candidate for oral therapy with a PDE-5 inhibitor?
Most men can take PDE-5 inhibitors. Nevertheless, there are certain contraindications to the use of these therapies. If these limitations are ignored, serious or even life-threatening problems may occur. Specific contraindications to the use of PDE-5 inhibitors include the use of products containing...
(100 Questions & Answers About Mens Health: Keeping You Happy & Healthy Below the Belt)